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SUMMARY
The high level of protection which can be induced by vaccination of a range of hosts, from rodents to primates, with live
radiation-attenuated schistosome larvae oﬀers great promise for development of a human schistosome vaccine. Studies of
the irradiated vaccine models beneﬁtted from signiﬁcant funding during the 1970–90s and much was learned concerning
the inducers, targets and mechanisms of immunity. Less progress was made in deﬁnition of the protective antigens
involved. The application of new techniques for identifying membrane and secreted antigens has recently provided new
vaccine candidates and a new impetus for schistosome vaccine development. This article is intended as an overview of some
of the main lessons learned from the studies of the irradiated vaccines as a backdrop to renewed interest in schistosome
vaccine development.
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INTRODUCTION
Schistosomiasis has been eradicated from a number
of areas of the world through valiant integrated con-
trol measures based on snail control, drug treatment
and environmental modiﬁcation. In many other en-
demic areasmorbidity has been dramatically reduced
in recent times by treatment with praziquantel, the
only drug now in widespread use (Fenwick and
Webster, 2006). In such areas the snail host popu-
lations remain unaﬀected, transmission persists and
reinfection is common. Relaxation of vigilance in
‘eradicated’ areas or of control eﬀorts in endemic
areas or development of resistance to praziquantel
would rapidly lead to resurgence of the disease. De-
spite the potential of regular chemotherapy to control
morbidity, the desirability of a vaccine to supplement
and sustain chemotherapy-based control eﬀorts re-
mains as high as in 1970–1990 (Taylor, 1994) when
schistosome vaccine research was reasonably well
funded. A particular focus of attention during this
time was on vaccination with radiation-attenuated
larval infections which were demonstrated to be
highly eﬀective in many experimental hosts (Taylor,
1994) and this encouraged belief in the feasibility
of developing a deﬁned schistosome vaccine for hu-
mans. Further studies of irradiated vaccines yielded
considerable understanding of the schistosome life-
cycle stages which are the optimal inducers and tar-
gets of such immunity but limited progress wasmade
into deﬁning and validating the protective antigens
involved. Other, parallel approaches to vaccine
development yielded several recombinant–derived
schistosome proteins which showed promise in their
labs of origin but less so when tested independently
(Bergquist and Colley, 1998). With this, the impetus
for vaccine development waned, particularly since
there was a general perception in the public health
community at this time that the schistosomiasis
problem could be ‘solved’ globally using population-
scale praziquantel treatment.
However, there is now a growing appreciation of
the limitations of what chemotherapy campaigns
alone can achieve, and recent application of pro-
teomic and genomic techniques has facilitated the
identiﬁcation and characterization of membrane and
secreted antigens, likely candidates for the protection
induced by irradiated vaccines. So it is timely to re-
view some of the lessons learned from the irradiated
vaccine work in the hope of encouraging the new gen-
eration of those who share the belief that schistosome
vaccines are both feasible and needed (Bergquist et al.
2005; Bethony et al. 2008). More exhaustive reviews
of irradiated vaccines (Coulson, 1997; Dean, 1983)
and of approaches to schistosome vaccine develop-
ment (e.g. Hewitson et al. 2005;Wilson andCoulson,
2006; McManus and Loukas, 2008) are available.
IRRADIATED VACCINES – ESTABLISHMENT OF
EFFECTIVE PROTOCOLS
Use of radiation-attenuated helminth infections to
induce protection was ﬁrst tested in the 1950s and,
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notably, led to development of the commercial live
vaccine Dictol1 against Dictyocaulus viviparus, a
nematode of cattle (Jarrett et al. 1958). The vaccine
comprised oral infection with larvae irradiated with
40 krad (kilorads) such that they did not reach the
adult pathogenic stage but survived long enough to
stimulate cells in the mesenteric lymph nodes.
Prompted by this success irradiated vaccines against
other helminths were soon being tested e.g. Miller
(1978). In the case of schistosomes, doses of 3–4 krad
of X- or c-radiation were shown to prevent develop-
ing schistosome worms surviving to the adult patho-
genic egg-laying stage while doses of 1–3 krad
resulted in persistence of a small proportion of
stunted and generally sterile adults (Smithers, 1962).
There followed various protection studies against
S. mansoni and S. japonicum in mice and repeatedly
exposed rhesus monkeys using cercariae exposed
to relatively low levels of radiation (Hsu et al. 1962;
Radke and Sadun, 1963; Sadun et al. 1964;
Smithers, 1962; Villella et al. 1961) and most studies
reported higher levels of partial protection to
challenge with very low doses of radiation which
allowed a small proportion of stunted worms to sur-
vive. These studies were carried out at a time when
the prevailing notion, based on studies in rhesus
monkeys harbouring unattenuated S. mansoni in-
fections (Smithers and Terry, 1965, 1967), was that
the adult worm is the prime stimulus to protection
and that the schistosomula stages contribute little to
the development of resistance. Thus, with respect to
these early irradiated infections Smithers (1976)
suggested that ‘… the immunizing eﬀect is pre-
dominantly due to the few stunted worms which
survive the lethal eﬀects of radiation’. However, Hsu
et al. (1969), wishing to avoid inﬂammatory foci in
the lung and liver due to death of immunizing larvae
in these organs, tested highly irradiated (24 or
48 krad) cercariae of S. mansoni and S. japonicum
which would arrest in the lung/skin. Both radiation
doses resulted in high levels of protection in rhesus
monkeys (>80% fewer worms than controls) es-
pecially after repeated (>3) infections.
In the early 1970s studies were initiated using the
schistosome species of domestic animals, S. mattheei
and S. bovis, which meant that vaccination eﬃcacy
could be assessed in natural hosts i.e. sheep and
cattle. Initial studies in sheep using 1 or 2 exposures
to S. mattheei larvae irradiated at 3 or 6 krad were
ineﬀective but high levels of partial protection>70%
could be induced following 4 vaccinations and
comparable protection could be induced with per-
cutaneously applied cercariae and intramuscularly
injected in vitro-transformed schistosomula (Taylor
et al. 1976b). Similar protection could be induced
against S. bovis in cattle with a single vaccination
(Bushara et al. 1978). These studies culminated in a
ﬁeld trial in cattle of an S. bovis vaccine comprising
a single intramuscular injection of schistosomula
irradiated at 3 krad (Majid et al. 1980). High partial
protection to natural exposure was demonstrated
and was followed by similar successful ﬁeld testing
of an irradiated, cryopreserved, schistosomula vac-
cine for S. japonicum in cattle and buﬀaloes, key
hosts of this zoonotic schistosome species (Hsu et al.
1984).
In the case of the human schistosome species,
S. mansoni, a similar approach was applied using
baboons, regarded as a suitable model for human
schistosomiais since these primates, unlike rhesus
monkeys, are natural hosts of both S. mansoni and
S. haematobium. However, repeated exposure to
larvae given low doses of radiation did not induce
signiﬁcant protection (Taylor et al. 1976a). This
failure prompted studies in mice and rats aimed at
deﬁning the key parameters for optimal vaccination
protocols. It was soon established that for resistance
induced by a single exposure of mice the dose of
radiation had a signiﬁcant eﬀect. Both low doses of
radiation, allowing parasite survival through to
stunted adult worms, and very high doses, arresting
the larvae in the skin, were poorly eﬀective whereas
signiﬁcantly higher protection could be induced with
optimal doses (56 krad (Minard et al. 1978a) or
20 krad (Bickle et al. 1979c)). In both cases the eﬀects
of these optimal doses of radiation on the larvae were
similar, resulting in a slight delay in the skin but
eventual migration to and death in the lungs (Minard
et al. 1978b ; Bickle et al. 1979b ; Mastin et al. 1983;
Mangold and Dean, 1984). The reasons for the nu-
merical diﬀerence in these optimal doses is not clear
but since at this early time most subsequent studies
in the USA, although not all (Reynolds and Harn,
1992), employed doses around 50 krad and in the
UK, 20 krad. In rats, 20 krad also arrested S. man-
soni larvae in the lungs and similarly proved to be an
optimal dose (Ford et al. 1984a).
The superior protective eﬃcacy of highly irra-
diated cercariae in mice led to renewed testing in
baboons and, similarly, somewhat greater protection
could be induced with optimally-irradiated infec-
tions. Thus, studies using S. haematobium (Sturrock
et al. 1980; Webbe et al. 1982; Harrison et al. 1990)
demonstrated high levels of protection (y90%) with
multiple (2–3) exposures to 20 krad cercariae whilst
lower protection was obtained with 3 krad or 60 krad
and signiﬁcantly less with a single vaccination
(y30%) (Harrison et al. 1990). Repeated exposure to
highly irradiated cercariae was also protective against
S. mansoni (Stek et al. 1981b) and could be boosted
by repeated exposures (Kariuki et al. 2004). Sig-
niﬁcant partial protection (y45%) was also demon-
strated in chimpanzees, our closest primate relative
(Eberl et al. 2001).
So, high levels of protection have been demon-
strated in a wide variety of hosts against various
schistosome species including the threemajor human
species. Choice of optimal radiation dose and use of
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multiple vaccinations are more crucial for some
species than others, notably primates.
INDUCERS AND TARGETS OF IMMUNITY
Nearly all of our further understanding of the mech-
anisms of immunity induced by irradiated infections
has come from studies of S. mansoni in mice, and to
some extent from rats. The fact that optimal doses of
radiation result in migration to and death in the lungs
focused attention on the immunogenicity of the lung-
stage schistosomula (LS) and led to experiments
showing that irradiated LS introduced into the lungs
via intravenous injection (Dean et al. 1981; Ford et al.
1984a), or into the skin (Coulson and Mountford,
1989) could confer immunity. Emphasis on the larval
stages was further supported by the relative failure
of irradiated 3- or 4-week-old worms (Dean et al.
1981) or unirradiated adult worm (single sex) in-
fections to induce protection in mice (Bickle et al.
1979a).
The LS was also shown, in the majority of studies,
to be the principal target of immunity in challenged
animals. By recovery of parasites following mincing
and incubation of tissue (Minard et al. 1978b ; Stek
et al. 1981a) by quantitative histology (Mastin et al.
1983; Von Lichtenberg et al. 1985) and most accu-
rately by autoradiographic tracking in compressed
organs (Dean et al. 1984; Wilson et al. 1986; Dean
and Mangold, 1992) it was shown that migration of
percutaneously applied challenge larvae to the lungs
is delayed in vaccinated compared with naı¨ve mice
but otherwise comparable. Subsequently, a greater
proportion of schistosomula are retained in the lungs
of vaccinated mice and these gradually disappear
between 2–5+ weeks post-infection (Wilson et al.
1986; Dean and Mangold, 1992). LS introduced
by i.v. injection into the lungs of vaccinated rats
(Ford et al. 1984b ; McLaren et al. 1985) and mice
(Mangold et al. 1986) were also highly susceptible
to attrition although, in some experiments in mice,
somewhat higher levels of resistance followed per-
cutaneous challenge (Smythies et al. 1996; Coulson
and Wilson, 1997) which the authors suggested in-
dicates that the skin stage may help to initiate a recall
response prior to lung attrition.
Histological studies of the response elicited by
percutaneously applied challenge infections in vac-
cinated mice showed pronounced inﬂammatory foci
around schistosomula in the skin and subsequently in
the lungs (Von Lichtenberg et al. 1985), for example,
by day 8 post-challenge there were >10-fold more
lung foci in vaccinated compared with control mice.
The cellular inﬁltration, comprising predominantly
mononuclear cells, starts as soon as the larvae reach
the lungs and peaks around 8 days after infection
(Smythies et al. 1996). Cells accumulate within the
blood vessel and between the vascular endothelium
and the alveolar epithelium resulting, it is suggested,
in the intravascular migration of the larvae being
impeded. Certainly, with time, an increasing pro-
portion of larvae occur within alveoli where they
induce even more pronounced foci (Crabtree and
Wilson, 1986). Although Von Lichtenberg et al.
(1985) described damaged LS in vaccinated mice,
Crabtree and Wilson (1986) found no evidence of
parasite damage and this led to the notion that LS
may not be killed within the lung but rather diverted
from their intravascular migration into the alveoli
and subsequently lost via the trachea and eventually
the GI tract. This was supported by later studies
showing that challenge LS recovered from lungs
of vaccinated mice over the extended period of at-
trition showed normal viability when injected into
naı¨ve mice (Coulson and Wilson, 1988). Further-
more, radio-isotope labelled, challenge organisms in
compressed lungs always appeared as discrete auto-
radiographic foci of equal intensity, unlike foci
caused when radio-isotope labelled, heat-killed LS
were injected into the lungs which became smaller
and fainter with time (Dean and Mangold, 1992).
The lack of evidence of in vivo death of LS is con-
sistent with the demonstration that they are also
insusceptible to immune damage in vitro by either
antibody- or cell-mediated mechanisms (Moser et al.
1980; Sher et al. 1982b ; Bickle and Ford, 1982;
Ahmed et al. 1997).
MECHANISMS OF IMMUNITY
Initial investigations into themechanisms of vaccine-
induced resistance in rodents implicated the immune
response since B cell-depleted mice and athymic
mice and rats failed to develop resistance (Sher et al.
1982a ; Ford et al. 1987a). Both antibody and CD4+
T-cell-mediated, IFN-c-dependent eﬀector mech-
anisms have been demonstrated, depending on the
host species and the number of vaccinations.
In mice, larvae from a percutaneuosly applied,
optimally irradiated infection undergo a protracted
migration in the skin (Mangold and Dean, 1984),
speciﬁcally in the skin draining lymph nodes (SLN),
and release greater amounts of parasite antigen than
unirradiated larvae (Mountford et al. 1988). This
results in marked increases in cell number (Constant
et al. 1990) and prolonged in vitro antigen-speciﬁc
CD4 +ve cell proliferation which is followed some
time later by similar events in the lungs and draining
mediastinal lymph nodes as larvae migrate there
(James et al. 1981; Lewis and Wilson, 1982;
Pemberton et al. 1991). Initial percutaneous ex-
posure to either normal or irradiated cercariae in-
duces both Th1 (IFN-c and IL-2) and Th2 (IL-5
and IL-4) cytokine responses in the SLN (Caulada-
Benedetti et al. 1991) but these are more protracted
with the irradiated infection and Th1 cytokines re-
sponses tend to increase preferentially at later time
points (Pemberton et al. 1991). Th1-polarized
Irradiated schistosome vaccines 1623
cytokine production is more prominent in the spleen
(Caulada-Benedetti et al. 1991; Pearce et al. 1991;
Pemberton et al. 1991) and the lungs (Smythies et al.
1992b). Based on an extensive series of studies (re-
viewed by Coulson, 1997) Wilson and colleagues
determined that the cells primed in the SLN enter
the systemic circulation and are recruited as eﬀector/
memory cells to the lung airways and draining medi-
astinal lymph nodes, this recruitment coinciding
with cell accumulation around irradiated larvae
reaching the lungs (Mastin et al. 1985). This cell re-
cruitment to the lung is dependent on the vaccinating
larvae reaching the lungs and is essential for optimal
immunity since naı¨ve mice parabiosed to vaccinated
partners show transfer of antigen-speciﬁc cells to the
spleen but not to the lung, and manifest lower re-
sistance (mean 35% lower) than their vaccinated
partners (Coulson and Wilson, 1997). In contrast
to the latter, the parabiosed mice are also unable to
resist an intravenous challenge with LS which is
consistent with the concept that optimally irradiated
larvae result in ‘arming’ of the lung with cells able
to respond rapidly to migrating LS (Wilson and
Coulson, 1989). These experiments and others
(Mountford et al. 1992) highlight the fact that the
high levels of immunity which can be induced in
mice by a single exposure to attenuated larvae cru-
cially depend on a proportion of the larvae surviving
to reach and die in the lungs.
Cell-mediated immunity (CMI)
A role for Th1-mediated immunity in mice exposed
once to irradiated cercariae was ﬁrst indicated by the
failure to induce resistance in CMI-deﬁcient P strain
mice (James and Sher, 1983) and later conﬁrmed by
the observation that signiﬁcantly lower resistance
occurred if CD4+ cells were depleted at the time
of challenge (Kelly and Colley, 1988; Vignali et al.
1989a). After challenge of vaccinatedmice, broncho-
alveolar lavage (BAL) cells increase markedly in
the lung and IFN-c production from CD4+ cells
dominates, peaking at day 14 as foci develop around
challenge parasites (Smythies et al. 1992b). Marked
increases in IFN-c, IL-12 p40, TNF-a, and iNOS
mRNA expression occur (Wynn et al. 1994, 1995)
and high levels of iNOS mRNA occur speciﬁcally
in the parasite-associated inﬂammatory foci (Wynn
et al. 1994). BAL cells also show highly elevated
nitric oxide (NO) production to a challenge of LS
administered i.v. (Coulson et al. 1998). However,
experiments designed to determine the contribution
of IFN-c and NO to protection in singly vaccinated
mice have reached somewhat varied conclusions.
Depletion of IFN-c during challenge with neu-
tralizing monoclonal antibody has been reported to
dramatically (Smythies et al. 1992a) or modestly
(Wynn et al. 1994; Jankovic et al. 1999) reduce pro-
tection. Similarly IFN-c Receptor KO mice show
marked reduction (y55%) in protection (Wilson
et al. 1996) whereas IFN-c KO mice show a modest
reduction (25%) (Jankovic et al. 1999). Use of iNOS
KO mice or inhibitors of NO production have led to
the conclusion that NO plays a modest role (reducing
protection byy30%) (James et al. 1998; Wynn et al.
1994) or no signiﬁcant role (Coulson et al. 1998) in
protection. Overall, these studies support a signiﬁ-
cant if not dominant role for CMI in singly vacci-
nated mice but Hewitson et al. (2007) have recently
questioned this since mice lacking CD154, which are
deﬁcient in both Th1 and IgG responses, fail to
develop protection when the Th1 component is re-
constituted by administration of IL-12.
Antibody-mediated immunity
Antibody contributes to immunity following single
vaccination in mice since protection is signiﬁcantly
(y30–50%) lower in B-cell-deﬁcient (mMT) com-
pared withWTmice (Anderson et al. 1999; Jankovic
et al. 1999) and transfer of serum from singly vacci-
nated WT donors restores mMT immunity to that in
WT mice (Jankovic et al. 1999). Following repeated
exposure of mice CMI becomes less important and
antibody more so. CD4+ cell depletion has less ef-
fect on protection after double vaccination (Vignali
et al. 1989a) and, following multiple (5r) vacci-
nation, depletion has no eﬀect which, together with
much enhanced antibody levels, indicates that any
CMI requirement is fully replaced by antibody-
mediated protection (Kelly and Colley, 1988). This
is consistent with the demonstration by Caulada-
Benedetti et al. (1991) that following repeated (3r)
exposure Th2 cytokines are upregulated at the ex-
pense of Th1 cytokines. Repeat vaccination also leads
to somewhat enhanced protection (Minard et al.
1978a ; Richter et al. 1993a ; Anderson et al. 1999;
Jankovic et al. 1999) and to boosting of antibody titres
(Delgado and McLaren, 1990; Caulada-Benedetti
et al. 1991; Anderson et al. 1999; Jankovic et al.
1999). This boosting of the antibody response
explains the increased protection since both occur
in IFN-c KO but not in B-cell-deﬁcient mice
(Anderson et al. 1999; Jankovic et al. 1999).
The ability of attenuated larval infections to in-
duce protective antibody was demonstrated directly
by passive transfer of protection with serum from
rabbits vaccinated with 20 krad-irradiated cercariae
(Ford et al. 1984b ; Bickle et al. 1985). Homologous
passive transfer of protection using sera from singly
or multiply vaccinated rats indicated that antibody is
the principal mediator of protection in rats (Ford
et al. 1984b, 1987b). Such serum transfer is equally
or more eﬀective at day 5, when the larvae are in
the lungs, than at the time of challenge, but less ef-
fective when the larvae reach the liver (Ford et al.
1984b ; Bickle et al. 1985; Mangold and Dean, 1992).
This demonstrates that irradiated vaccine-induced
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antibody is eﬀective against LS which were ﬁrst
shown to be a target of immunity in passive transfer
experiments using serum from rats infected with
unattenuated larvae (Mangold and Knopf, 1981).
Using a diﬀerent strain of ratMcLaren and Smithers
(1985) found that passive transfer of vaccinated rat
serum was eﬀective at day 5 post-challenge but
not at day 0 and was also eﬀective against a challenge
of LS delivered into the lung via tail vein injection
if given on the same day but not 4+ days later.
This demonstration of the unique susceptibility
of the lung stage is consistent with the observed
lung-stage attrition of the challenge infection in
vaccinated rats (Ford et al. 1984b). The protection
was shown to be mediated by IgG2a (Ford et al.
1987b), the major isotyope in rats (Bazin et al. 1974)
and by IgG in rabbit serum (Mangold and Dean,
1992).
Homologous passive transfer in mice was ﬁrst
shown by Mangold and Dean (1986) (50–85%
transfer of the resistance of the donors). Successful
transfer depended on the donormice receiving repeat
(2 or more) vaccinations and, for optimal protection,
for the serum to be given at the lung stage (6–10 days
post-challenge) rather than at the time of challenge.
Similar results were obtained by Richter et al.
(1993a) and forS. japonicum byMoloney andWebbe
(1990). However, McLaren and Smithers (1988)
who, in contrast to other workers (Mastin et al. 1983;
Von Lichtenberg et al. 1985; Dean et al. 1984;
Wilson et al. 1986; Dean and Mangold, 1992) had
described challenge parasite attrition in the skin of
vaccinated mice (Kamiya et al. 1987) reported mark-
edly higher protection when serum was transferred
at the skin rather than at the lung stage. Various
studies have shown that IgG1, IgG2a and IgG2b are
boosted following multiple vaccination of mice al-
though IgG1 is themost prominent isotype (Delgado
and McLaren, 1990; Caulada-Benedetti et al.
1991; Wynn et al. 1996). By passive transfer, IgG
(Mangold and Dean, 1986) and speciﬁcally IgG1
(Delgado and McLaren, 1990) have been identiﬁed
as protective isotypes but the non-IgG serum frac-
tion has also been implicated (Jwo and LoVerde,
1989).
In primates, repeated exposures are needed to in-
duce modest to high levels of protection and result
in boosting of antigen-speciﬁc IgG, levels of which
correlate with protection (Harrison et al. 1990) ;
Soisson et al. 1993; Yole et al. 1996). This indicates
that antibody plays a major role in irradiated vaccine
immunity in primates.
Regarding the mechanism of antibody-mediated
attrition, mice vaccinated with repeat (2 or 3) ex-
posures and in which antibody is believed to play a
key role, show essentially similar mononuclear cell-
rich foci around challenge LS in the lung (Vignali
et al. 1988a ; Kassim et al. 1992) as have been de-
scribed for singly vaccinated mice (Crabtree and
Wilson, 1986). Again the larvae appear undamaged
and a proportion of them occur within alveoli, in
which case they induce marked inﬂammatory re-
sponses (Kassim et al. 1992). McLaren and Smithers
(1988) reported that transfer of immune serum at the
skin stage elicited inﬂammatory reactions of mono-
nuclear cells and eosinophils around schistosomula
in the skin which, nevertheless, appeared morpho-
logically similar to LS and so even in this model
of apparent skin phase attrition, lung-form larvae
appear to be the target. In rats, where there is con-
sensus that challenge attrition occurs in the lungs of
vaccinated animals (Ford et al. 1984b ;McLaren et al.
1985) passive transfer of immune serum to naı¨ve rats
5 days post-infection, when the challenge parasites
are in the lungs, elicits an enhanced and accelerated
inﬂammatory mononuclear cellular inﬁltration
around the larvae compared with normal serum
(Vignali et al. 1989b) as shown in Fig. 1. Because in
mice there is no evidence of parasite damage or of
intimate cellular attachment, cellular accumulation
interfering with parasite migration (Crabtree and
Wilson, 1986) is a plausible cause of parasite loss.
How IgG is able to mediate such inﬂammatory foci is
unknown. Protection occurs in FccR KO mice
(Jankovic et al. 1999) and so Fc-receptor-mediated
activation of cells for ADCC in not required. In rats,
complement depletion during passive transfer at the
lung stage signiﬁcantly reduces protection (Vignali
et al. 1988b) and so generation of the chemoat-
tractants C3a and C5a by antibody/antigen ﬁxation
of complement may play a role in focus formation, at
least in the rat. Other possible roles of antibody in
interfering with parasite migration/viability by bind-
ing to surface receptors or signalling molecules re-
main to be assessed.
Fig. 1. Antibody-mediated mononuclear cell inﬁltration
around a lung-stage schistosomulum induced by
homologous passive transfer of vaccinated rat serum.
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THE ANTIGENS INVOLVED
Although not all studies agree, the weight of evidence
from mice and rats is that the lung schistosomula
alone can induce high levels of protection and that
they are the only necessary targets eliciting cell- or
antibody-mediated reactions during lung transit. It
follows that the protective antigens are those re-
sponsible for the induction of lung foci such as shown
in Fig. 1. Antigens responsible for T cell-mediated
focus formation would be soluble or secreted anti-
gens available to antigen presenting cells. Antibody
could bind to such secreted antigens but could also
bind to exposed epitopes of integral membrane anti-
gens. Although the LS shows minimal surface anti-
genicity as judged by immunoﬂuorescence (Pearce
et al. 1986) sera from vaccinated animals can mediate
transient cell adherence (Bickle and Ford, 1982;
Lawson et al. 1993) indicating that antibody does
have access to exposed larval antigens.
It follows that investigation of the vaccine potential
of the secreted and membrane antigens of LS is a
rational approach and soluble extract of in vitro-
derived LS is indeed able to induce signiﬁcant
protection in mice (Mountford et al. 1996). To
characterize the LS antigens Harrop et al. (1999)
used antisera against products released by such larvae
in culture to screen Western blots of cercarial, LS
and adult antigens. No LS-speciﬁc antigens were de-
tected and when the sera were used to screen cDNA
libraries most clones corresponded to previously
described immunodominant antigens whose rep-
resentation in the LS culture supernatant may have
been due to release from damaged larvae. Cercariae,
in vitro-derived schistosomula and adult worms are
muchmore ready sources of antigen for study than in
vivo-derived LS, but whether these stages share the
protective LS antigens involved in irradiated vaccine
immunity or whether these are transiently expressed
during larval development in vivo is uncertain.
However, strong protection (y90%) can be induced
in mice with repeated (5r) exposure to very highly
irradiated (e.g. 100 krad) cercariae which die in the
skin (Hsu et al. 1981) and comparable levels of pro-
tection to those demonstrated with LS (Mountford
et al. 1996) can be induced with cercarial, in vitro-
derived schistosomula or adult antigens given with
BCG intradermally (James et al. 1985). So the early
larval and adult stages clearly manifest antigens
which can induce protection. Recently, newer tech-
nologies for characterizing membrane and secreted
antigens have been applied to analysis of schistosome
adult worm proteins. Rigorous proteomic analysis
has led to identiﬁcation and characterization of a
large number of adult tegumental (Braschi et al.
2006) and surface-associated (Braschi and Wilson,
2006) proteins. Cloning of genes with signal se-
quences has allowed identiﬁcation of adult proteins
targeted for secretion or surface expression (Smyth
et al. 2003). Application of suchmethods has recently
led to identiﬁcation of tegumental proteins able to
induce protection inmice e.g. the tetraspanins, TSP-
1 and TSP-2 (Tran et al. 2006) and Sm29 (Cardoso
et al. 2008). Their involvement in irradiated vaccine
immunity and exposure on the surface of living
worms remains to be established although Sm29 has
been shown to be expressed by the LS tegument
(Cardoso et al. 2008).
Various approaches have been applied to identify
antigens speciﬁcally recognized by vaccinated ani-
mals e.g. characterizing larval surface antigens rec-
ognized by vaccine serum (Simpson et al. 1983) ;
generating monoclonal antibodies against larval
surface antigens using vaccinated donors (Bickle
et al. 1986; Dalton et al. 1987) ; testing known
recombinant-derived antigens for reactivity with
antibody or cells from vaccinated mice (Richter and
Harn, 1993; Richter et al. 1993b) ; identiﬁcation of
recombinant-derived antigens uniquely or preferen-
tially recognized by irradiated vaccine serum (com-
pared with infection serum) (Soisson et al. 1992;
Francis and Bickle, 1992). Some of these antigens
were included in the independent vaccine testing
(Bergquist and Colley, 1998) but others remain to be
characterized and tested. Amongst these are larval
surface antigens uniquely recognized by vaccine
serum but not by infection serum, e.g. 15 kDa
(Simpson et al. 1983) and 16 kDa (Bickle et al. 1986)
antigens and which appear to have transient ex-
pression in the larval stages (Bickle and Oldridge,
1999). Deﬁnition of such larval surface antigens will
likely need application of those techniques so suc-
cessfully applied to the adult tegument. It should be
noted that it is not yet clear whether any of the above
antigens or the many other schistosome antigens
identiﬁed by other means, play a signiﬁcant role in
irradiated vaccine-induced immunity and speciﬁcally
in mediating lung focus formation.
PROSPECTS FOR A DEFINED VACCINE
The evidence from the irradiated vaccine models
suggests that provided the immunogenic moieties
can be produced, protective immune responses
may not be particularly challenging to induce. Thus,
althoughWTmice, whichmake a balancedTh1/Th2
response, develop optimal immunity, high partial
protection occurs in cytokineKOmice whetherTh1-
or Th2-polarized responses are induced (Hoﬀmann
et al. 1999).
To simulate the antibody-mediated protection
induced by irradiated vaccines IgG antibodies will
be needed rather than IgE antibodies which are im-
plicated in naturally-acquired resistance in humans
(Hagan et al. 1998). Longevity of suﬃciently high
antibody titre will be a requirement. Based on ir-
radiated vaccine studies in various host species, im-
munizing regimens which are believed to induce
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antibody-mediated immunity have been shown to
lead to long-lived protection (Dean 1983; Hsu et al.
1981; Bickle et al. 1979d ; Ford et al. 1984a) although
some decline in protection with time has been shown
in baboons (Harrison et al. 1990).
A vaccine aimed at reproducing the CMI mech-
anisms which help mediate protection in singly vac-
cinated mice faces a number of challenges. It would
need to induce the lung sensitization required for
optimal immunity in this model and this is likely to
require targeting vaccine delivery to the lung as
proposed, for example, for TB vaccines (Kallenius
et al. 2007). It would need to induce Th1 responses
but avoid over-induction of regulatory cytokines e.g.
IL-10, since this can prevent manifestation of re-
sistance (Oswald et al. 1998). Challenge exposure
downregulates the Th1 response in mice (Pemberton
andWilson, 1995) and in the likely event of a vaccine
inducing only partial protection the ensuing egg
production is likely to profoundly alter the response
from a Th-1 to a Th2-dominated response, as occurs
when schistosome eggs are injected into vaccinated
mice (Pearce et al. 1991). Furthermore, in endemic
areas, vaccinees are likely to have an underlying Th2
biased response due to other worm infections or to
previously treated schistosome infections that could
interfere with the generation of Th1 responses. Re-
garding the inﬂuence of current/previous infection
on vaccine eﬃcacy it is encouraging that studies in
baboons have shown that multiple irradiated vaccine
regimens, likely to induce antibody-mediated pro-
tection, are equally eﬀective in naı¨ve and in infected
or infected and previously treated animals (Kariuki
et al. 2006).
Given the availability of a new crop of promising
protective antigens and the enthusiastic application
of new technologies for indentifying membrane and
secreted antigens a schistosome vaccine modelled on
the irradiated vaccine seems increasingly technically
feasible. However, as Loukas et al. (2007) urged,
development of this promise into a human vaccine
will require the wheel to turn and signiﬁcant inves-
tment to return to schistosome vaccine development.
I am very grateful to Martin Taylor and Helena Helmby
for critical review of this manuscript.
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